Latest available resultsQuarter ended June 27, 202610-Q · August 5, 2026
Filed with the SECCHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CRLHealthcare
Next reportNovember 3, 2026pre-market · Analyst forecast 2.982 $/share
Revenue
$1.00B
▼ -2.7% vs prior year% YoY
Net income
−$1.48M
▼ -102.8% vs prior year% YoY
EPS
-0.03$
▼ -102.8% vs prior year% YoY
Net margin
-0.1%
▼ -5.2 percentage points vs prior year pp YoY
Revenue▼ -2.7 %
Margins (% of revenue)GrossOperatingNet
Net income▼ -102.8 %
EPS▼ -102.8 %
View financial tableQuarter ended June 27, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $1.00B | |
| Gross profit | — | |
| Operating income | $119.89M | 11.9 % |
| Net income | −$1.48M | -0.1 % |
| R&D | — | never filed |
| EPS (diluted) | -0.03 $ | |
| Balance sheet | ||
| Assets | $7.53B | |
| Liabilities | $4.64B | |
| Equity | $2.85B | |
| Cash | $192.03M | |
| Capital | ||
| Shares outstanding | 47.74M | as of 2026-07-25 |
| Public float | — | |